Previous Close | 1.17 |
1-Year Change | 11.43% |
6-Months Change | 32.95% |
3-Months Change | -38.42% |
Moving Avg (50d) | 1.5846 |
Moving Avg (200d) | 1.1093 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 207.3M |
Beta (3-Years) | 1.83 |
Revenue Growth (ttm) | 79.75% |
Net Profit Margin (ttm) | -123.89% |
Return On Assets (ttm) | -113.58% |
EPS (ttm) | -1.45 |
PE Ratio (ttm) | -0.81 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases. Wikipedia